ACTRN12607000021471已完成3 期
A randomised phase III study to evaluate whether Ultraviolet Radiation B lowers blood pressure and insulin resistance and improves cardiac function in people with low vitamin D levels
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 50 Years 至 ot stated（—）
- 性别
- All
入选标准
- •Age - Pacific Island and Maori >50years, European >65years; 25OHD levels < 50 nmol/L.
排除标准
- •Hypertension treated with thiazide diuretics, diabetes treated with insulin or oral hypoglycaemics, taking vitamin D supplements (including cod liver oil), planned travel to areas with high sun exposure during the study period.
研究者
相似试验
已完成
不适用
BOOST-NZThe role of oxygen saturation targetting in morbidity and mortality in infants born less than 28 weeks gestationReproductive Health and Childbirth - Childbirth and postnatal careACTRN12605000253606niversity of Otago320
已完成
3 期
A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone in elderly patients with previously untreated systemic peripheral T-cell lymphomasT-cell lymphoma10025321NL-OMON41578niversity Medicine Goettingen25
尚未招募
3 期
A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone and consolidated by autologous stem cell transplant, in young patients with previously untreated systemic peripheral T-cell lymphomasT cell lymphoma10025321NL-OMON31642ordic Lymphoma Group40
进行中（未招募）
1 期
A phase III, randomised study to evaluate the clinical consistency in terms of immunogenicity and reactogenicity of three production lots of the liquid formulation of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine and to evaluate the liquid formulation as compared to the lyophilised formulation of the HRV vaccine in terms of immunogenicity, reactogenicity and safety when administered as a two-dose primary vaccination in healthy infants previously uninfected with HRV. - rota-061Two-dose immunisation at 3 and 4 months of age in healthy infants previously uninfected with HRV.EUCTR2006-003239-61-FIGlaxoSmithKline Biologicals1,200
进行中（未招募）
1 期
A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly) - A-CHOP-14 (elderly)Primary therapy of patients with Alk-negative T-NHL in patients aged 61 - 80 yearsICD classification codes : ICD-O 9702/39717/39716/39708/39705/39714/3MedDRA version: 9.1Level: LLTClassification code 10002464Term: Angiomimmunoblastic (AILD, LgX (Kiel Classification)MedDRA version: 9.1Level: LLTClassification code 10025632Term: Malignant lymphomaEUCTR2007-000821-23-BEniversity Medicine Goettingen274